These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29384829)

  • 1. Oculomotor Nerve Demyelination Secondary to Certolizumab Pegol.
    Ban BH; Crowe JL
    J Clin Rheumatol; 2018 Jun; 24(4):234-236. PubMed ID: 29384829
    [No Abstract]   [Full Text] [Related]  

  • 2. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
    Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
    J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Certolizumab Pegol-Induced Heart Failure.
    Lazarewicz K; Shaw S; Haque S
    J Clin Rheumatol; 2018 Jan; 24(1):55-56. PubMed ID: 29232326
    [No Abstract]   [Full Text] [Related]  

  • 4. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.
    Deeks ED
    BioDrugs; 2016 Dec; 30(6):607-617. PubMed ID: 27704400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyethylene glycol: an underrecognized compound in certolizumab pegol and Movicol that may cause anaphylaxis.
    McCabe E; Tormey V; Doran JP
    Rheumatology (Oxford); 2020 Apr; 59(4):908-910. PubMed ID: 31598712
    [No Abstract]   [Full Text] [Related]  

  • 6. Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies.
    Domańska B; Stumpp O; Poon S; Oray S; Mountian I; Pichon C
    Adv Ther; 2018 Jan; 35(1):100-115. PubMed ID: 29222625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nail Psoriasis Treated With Certolizumab Pegol in Patients With Psoriatic Arthritis: Preliminary Observation.
    Mazzeo M; Dattola A; Cannizzaro MV; Bianchi L
    Actas Dermosifiliogr (Engl Ed); 2019 Mar; 110(2):169-171. PubMed ID: 29866366
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of psoriatic alopecia secondary to certolizumab pegol: clinical and trichoscopic evaluation.
    Lauro W; Picone V; Abategiovanni L; Vastarella M; Gallo L; Fabbrocini G; Megna M
    Int J Dermatol; 2023 Feb; 62(2):e70-e72. PubMed ID: 35579302
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report.
    Horai Y; Ishikawa H; Iwanaga N; Izumi Y; Matsuoka Y; Miura S; Kawakami A
    J Clin Pharm Ther; 2020 Oct; 45(5):1179-1182. PubMed ID: 31990069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synovitis acne pustulosis hyperostosis osteitis (SAPHO) - paradoxical reactions and different responses to tumour necrosis factor inhibitors.
    Liew J; Xu TH; Chu CQ
    Rheumatology (Oxford); 2017 Dec; 56(12):2239-2241. PubMed ID: 28977552
    [No Abstract]   [Full Text] [Related]  

  • 12. Certolizumab pegol, a pegylated anti-TNF-α antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis.
    Koizumi H; Tokuriki A; Oyama N; Ido H; Sugiura K; Akiyama M; Hasegawa M
    J Dermatol; 2017 Jun; 44(6):723-724. PubMed ID: 27599405
    [No Abstract]   [Full Text] [Related]  

  • 13. Infections and Biological Therapy in Patients with Rheumatic Diseases.
    Atzeni F; Batticciotto A; Masala IF; Talotta R; Benucci M; Sarzi-Puttini P
    Isr Med Assoc J; 2016; 18(3-4):164-7. PubMed ID: 27228636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypersensitivity reaction to certolizumab pegol in a patient affected by psoriatic arthritis.
    Napolitano M; Gallo L; Megna M; Fabbrocini G; Nocerino M; Abategiovanni L; Patruno C
    Dermatol Ther; 2019 May; 32(3):e12900. PubMed ID: 30964566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Use of Certolizumab Pegol for Refractory Psoriatic Arthritis Triggered by COVID-19 Infection.
    Ohmura SI; Homma Y; Hanai S; Miyamoto T
    Intern Med; 2022 Feb; 61(3):433-438. PubMed ID: 34803106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab-associated third nerve palsy.
    Farukhi FI; Bollinger K; Ruggieri P; Lee MS
    Arch Ophthalmol; 2006 Jul; 124(7):1055-7. PubMed ID: 16832034
    [No Abstract]   [Full Text] [Related]  

  • 17. [TNF inhibitors].
    Kameda H
    Nihon Rinsho; 2016 Jun; 74(6):957-62. PubMed ID: 27311185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, open-label study to evaluate the safe and effective use of a new electromechanical auto-injection device for self-injection of certolizumab pegol.
    Tatla D; Mountian I; Szegvari B; VanLunen B; Schiff M
    Expert Opin Drug Deliv; 2020 Jun; 17(6):855-862. PubMed ID: 32239971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
    Cisternas M; Gutiérrez M; Jacobelli S
    Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
    [No Abstract]   [Full Text] [Related]  

  • 20. Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: Report of a case and review of the literature.
    Babuna Kobaner G; Polat Ekinci A; Yilmaz Z; Copur S
    Dermatol Ther; 2018 Sep; 31(5):e12693. PubMed ID: 30225952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.